Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
June 1, 2024Journal of Clinical Oncology

KPG-121, a novel cereblon modulator, in patients with metastatic castration resistant prostate cancer: Results of a phase I multiple ascending dose study.

View Full Paper
Ask AI
Bookmark
Share

Authors

MDMichael DevittRZRichard Michael ZunigaATAlfredo Torres

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Devitt et al. (2024) studied this question.

synapsesocial.com/papers/68e67065b6db6435875faf2dhttps://doi.org/10.1200/jco.2024.42.16_suppl.e17054
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Kpg-818, a novel cereblon (CRBN) modulator, in patients with hematological malignancies: Results of a Phase 1, open-label, multiple ascending dose study2025
  2. 2Phase 1, multicenter, open-label study of HSK46575 in patients with metastatic castration-resistant prostate cancer progressing after next-generation hormonal agents and chemotherapy.2026
  3. 3Pembrolizumab plus Abiraterone Acetate and Prednisone in Patients with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Results from KEYNOTE-365 Cohort D2024 · 7 citations
  4. 4Biomarker assessment and pharmacology of HP518, an AR PROTAC degrader from the phase 1 dose-escalation study in patients with metastatic castration-resistant prostate cancer (mCRPC).2024 · 2 citations
  5. 5Safety and efficacy of QLC5508 (MHB088C) in heavily-treated patients with metastatic castration-resistant prostate cancer: Updated data from a phase 1/2 trial.2026 · 1 citations